Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 115 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $171,862 | -20.5% | 14,227 | +7.1% | 0.00% | – |
Q1 2024 | $216,063 | +138.9% | 13,288 | +0.2% | 0.00% | – |
Q4 2023 | $90,441 | +40.8% | 13,261 | +12.5% | 0.00% | – |
Q3 2023 | $64,223 | -19.7% | 11,784 | 0.0% | 0.00% | – |
Q2 2023 | $80,013 | +18.0% | 11,784 | -12.9% | 0.00% | – |
Q1 2023 | $67,785 | -3.2% | 13,530 | -5.7% | 0.00% | – |
Q4 2022 | $70,023 | -71.1% | 14,349 | -14.6% | 0.00% | – |
Q3 2022 | $242,000 | -86.1% | 16,803 | -85.4% | 0.00% | -100.0% |
Q2 2022 | $1,745,000 | +869.4% | 115,302 | +661.4% | 0.00% | – |
Q1 2022 | $180,000 | -26.2% | 15,144 | +0.7% | 0.00% | – |
Q4 2021 | $244,000 | -48.0% | 15,033 | -8.5% | 0.00% | – |
Q3 2021 | $469,000 | +0.2% | 16,429 | +18.5% | 0.00% | – |
Q2 2021 | $468,000 | +82.1% | 13,866 | +63.1% | 0.00% | – |
Q1 2021 | $257,000 | -18.2% | 8,503 | +34.2% | 0.00% | – |
Q4 2020 | $314,000 | -91.5% | 6,334 | -92.6% | 0.00% | -100.0% |
Q2 2020 | $3,674,000 | – | 85,061 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 191,176 | $2,757,000 | 9.37% |
Sofinnova Investments, Inc. | 2,194,278 | $31,641,000 | 1.84% |
MPM BioImpact LLC | 443,702 | $6,398,000 | 1.52% |
Artal Group S.A. | 400,000 | $5,768,000 | 0.25% |
Polar Capital Holdings Plc | 2,531,546 | $36,505,000 | 0.23% |
ASHFORD CAPITAL MANAGEMENT INC | 101,970 | $1,470,000 | 0.22% |
Lombard Odier Asset Management (Switzerland) SA | 168,795 | $2,434,000 | 0.21% |
Soleus Capital Management, L.P. | 87,182 | $1,257,000 | 0.17% |
Cormorant Asset Management, LP | 150,000 | $2,163,000 | 0.15% |
Walleye Capital LLC | 437,344 | $6,307,000 | 0.12% |